An interview by News Medical with David James, CEO J+D Forecasting about pharmaceutical forecasting, J+D Forecasting solutions and their plans for the future.
Generating accurate forecasts for rare diseases can be challenging, especially when the treatable population is in the hundreds and there is little data to get you from one number to the next.
Forecasting is essential in providing clarity on decision making about the future, and good quality forecasts can prevent decisions being made which could be commercially damaging to organisations.
J+D were approached by a global pharmaceutical company with a broad pipeline across rare diseases, who needed an improved forecasting approach to evaluate a new extension line in greater detail and gain valuable insight from affiliates.
J+D were approached by a global pharmaceutical company who needed a new forecasting solution with a robust process management system to give them a solid foundation when forecasting their pipeline assets.
The adoption of Onco+ has helped this biotech cut the forecast development pipeline significantly and supported best practice forecasting within their team.
J+D, Global Pharmaceutical Forecasting experts are excited to announce the launch of the next generation of FC365, the all-in-one, pharmaceutical forecasting platform that will transform the working practices of forecasting teams everywhere.